tetano
Editor, Senior Moderator
J Rheumatol. 2020 Apr 2. pii: jrheum.200369. doi: 10.3899/jrheum.200369. [Epub ahead of print]
Hydroxychloroquine: a potential ethical dilemma for rheumatologists during the COVID-19 pandemic.
Scuccimarri R[SUP]1[/SUP], Sutton E[SUP]1[/SUP], Fitzcharles MA[SUP]1[/SUP].
Author information
Abstract
Two antimalarial agents, chloroquine (CQ) and hydroxychloroquine (HCQ), have been trusted treatments for a range of rheumatic diseases over the past seventy years [1]. These agents have attracted intense media attention in the past few weeks with suggestions that this category of drugs may have potential in the management of coronavirus (SARS-CoV2) associated disease called COVID-19 [2, 3].
PMID:32241801DOI:10.3899/jrheum.200369
Hydroxychloroquine: a potential ethical dilemma for rheumatologists during the COVID-19 pandemic.
Scuccimarri R[SUP]1[/SUP], Sutton E[SUP]1[/SUP], Fitzcharles MA[SUP]1[/SUP].
Author information
Abstract
Two antimalarial agents, chloroquine (CQ) and hydroxychloroquine (HCQ), have been trusted treatments for a range of rheumatic diseases over the past seventy years [1]. These agents have attracted intense media attention in the past few weeks with suggestions that this category of drugs may have potential in the management of coronavirus (SARS-CoV2) associated disease called COVID-19 [2, 3].
PMID:32241801DOI:10.3899/jrheum.200369